2142 — HBM Holdings Share News
0.000.00%
Last trade - 00:00- HK$9.03bn
- HK$6.91bn
- $157.98m
Brief: Nona Biosciences Enters Into A Global License Agreement With Pfizer
Brief: HBM Announces US FDA IND Clearance For HBM9033 Clinical Trial Initiation
Brief: HBM Holdings Posts HY Profit $2.9 Mln
Brief: GIC Private Ltd's Long Position In Ordinary Shares Of HBM Holdings Falls To 4.99% - Filing
HK-listed HBM jumps on H1 profit expectations
Brief: HBM Holdings Gives Further Business Update Of Collaboration On Antibody-Drug Conjugate
Brief: HBM Sees Total Revenue Of Group For Six Months To Be US$40.0 Mln
Brief: HBM Holdings Says Biologics License Application For Batoclimab (Hbm9161) Accepted By NMPA
Brief: Nona Biosciences Enters Into Antibody Discovery Agreement With Opko Health's Modex Therapeutics
Brief: Harbour Biomed Announces Results Of Phase Ib Clinical Trial Of Porustobart In Combination With Toripalimab In Advanced High-Grade Neuroendocrine Neoplasms At Aacr Annual Meeting
Brief: HBM Holdings Announces Positive Topline Results Of Phase III Clinical Trial Of Batoclimab
HK-listed HBM jumps on licensing deal with Cullinan Oncology
Brief: HBM Holdings Says Unit And Cullinan Oncology Enters License And Collaboration Agreement
Brief: HBM Holdings Says Hbm1022 Receives Clearance From FDA Of United States
Brief: HBM Holdings Says U.S. FDA IND Clearance For HBM1007 Clinical Trial Initiation
Brief: HBM Says FDA Of United States IND Clearance For HBM1020 Clinical Trial Initiation
HK-listed antibody firm HBM jumps most on record on deal to license products
Brief: HBM Holdings Says Unit & Sichuan Kelun-Biotech Biopharmaceutical Entered License Agreement
Brief: HBM Says Unit Enters Collaboration Agreement With Dragonfly Therapeutics